Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 LEI · 549300CZ6Y0WSURPE203 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 494 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
Underwriting or agency agreements (or amendment thereto).pdf
Capital/Financing Update Classification · 95% confidence The document is an Underwriting Agreement for the sale of 24,000,000 common shares and accompanying warrants. It details the terms of a public offering, underwriters, prospectus supplements, registration statements and distribution logistics. This is a primary financing transaction, not an earnings release, management discussion, or regulatory attestation. It represents a capital-raising arrangement, fitting squarely under ‘Capital/Financing Update.’
2026-05-22 English
News release - English.pdf
Capital/Financing Update Classification · 92% confidence The document is a press release announcing the pricing of a US$60 million public offering of common shares and warrants – clearly a fundraising / financing activity. It details share issuance terms, offering size, pricing, use of proceeds, and listing of underwriters. This fits the Capital/Financing Update category (CAP).
2026-05-22 English
Draft shelf prospectus supplement – English.pdf
Share Issue/Capital Change Classification · 85% confidence The document is a preliminary prospectus supplement and shelf prospectus for an equity offering of common shares and warrants, describing the terms of a new issue of securities, underwriting agreements, pricing, and distribution plan. It is clearly a capital-raising / share issuance filing rather than a routine report or a proxy. The most specific category for this type of offering document is Share Issue/Capital Change (SHA).
2026-05-21 English
News release - English.pdf
Capital/Financing Update Classification · 97% confidence The document is a press release announcing the commencement of an underwritten public offering of common shares, warrants, and pre-funded warrants, detailing use of proceeds, prospectus details, and offering conditions. This clearly represents a capital/financing update rather than a financial report, governance filing, or other category.
2026-05-21 English
News release - English.pdf
Earnings Release Classification · 93% confidence The document is a press release titled “NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates,” containing summarized quarterly financial metrics (cash, R&D expenses, net loss per share) alongside business highlights and forward‐looking statements. It is not a full interim report with detailed statements but rather the initial announcement of quarterly results. Therefore, it matches the definition of an Earnings Release (ER). Q1 2026
2026-05-18 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a Form 52-109F2 certification by the CEO attesting to the interim financial report and MD&A for the period ended March 31, 2026. It does not contain the actual interim financial data but is an officer attestation under NI 52-109. Per the certification rule, such documents are classified as Regulatory Filings (RNS), not as the interim report itself.
2026-05-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.